News summary

Incremental Value of PAX1 Promoter Methylation for Histologic HSIL+ Risk Stratification After Aptima HPV E6/E7 mRNA Testing and 16/18/45 Genotyping: A Real-World Study

Source: Frontiers - Health • Published: 21 Nov 2026, 00:00

Summarized by Masters of Longevity from Frontiers - Health.

PAX1 promoter methylation was independently associated with histologic HSIL+ after Aptima HPV testing.

Incremental Value of PAX1 Promoter Methylation for Histologic HSIL+ Risk Stratification After Aptima HPV E6/E7 mRNA Testing and 16/18/45 Genotyping: A Real-World Study
Key Takeaways
  • PAX1 methylation was associated with higher HSIL+ odds.
  • Adding PAX1 modestly improved AUC versus clinical baseline model.
  • The single-center observational design means causality remains unproven.
Read the full article at Frontiers - Health ↗

Continue exploring

Recommended MoL Picks

MoL PickBiotin for Hair Growth: The Weak Evidence—and the Blood-Test Risk Most People MissBiotin deficiency can affect hair. That does not mean more biotin makes healthy hair grow—and high doses can distort important laboratory results.MoL PickApoB: The cholesterol signal LDL can missIn longevity medicine, the useful biomarkers are not always the exotic ones. ApoB is a relatively simple blood test that can sharpen cardiovascular prevention when LDL-C looks reassuring but particle burden remains high.MoL PickPlan Your Health Tests in Three MinutesThe free Personal Health Diagnostics Planner turns a short questionnaire into a ranked, personalised PDF: a clearer starting point for deciding which health checks deserve attention now.